Celldex Therapeutics, Inc. (CLDX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celldex Therapeutics, Inc. on August 6, 2026. The filing serves to announce the Company's financial results for the second quarter of 2026. The detailed results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the cover page text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the incorporated press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, except as expressly set forth by specific reference.
Key Facts for Investor Verification
- Verify the specific Q2 2026 financial results (revenue, net loss, cash position) in the attached Exhibit 99.1 press release.
- Confirm the Company's cash runway and liquidity status as of June 30, 2026, which are not listed in this summary text.
- Review the press release for any updates on clinical trial progress or regulatory milestones for the Company's product candidates.
- Note that the financial data in the press release is not considered "filed" under Section 18 of the Exchange Act.